Date & Time: 3rd July 2025 11am UTC


  • Users' discussions about the SNOMED International Drug Model and National Drug Extension Model.

Attendees:



Link: https://snomed.zoom.us/my/deusg?pwd=AypAgYBV0fzn7G0ZAaXCqzMz1gP5LE.1


Link:

Passcode:


Discussion items

Item

Description

Mins

Owner

Notes & Actions

1Opening2

Shane Byrnes 
Alejandro Lopez Osornio

Welcome & Notification of Recording

2Substances Co-ordination10

Krista Lilly Alejandro Lopez Osornio 

Updates on Substances Co-Ordination:

  • Step 1: Substances in multiple extensions
  • Step 2: Substances in one extension
    • Country self-review/first pass
    • Then, SI will review in scope
3Hydration - Demonstrate Examples35

Yongsheng Gao 

Guillermo Reynoso Linda Bird 

Updates on development work in relation to hydration substances.

  • SI
  • Canada
4Vaccine Substances2Shane Byrnes 

For Information: WHO recommended flu vaccine antigen substances for 2025/2026 season (Northern Hemisphere) are now available in International Release

5Has Container Type5

Linda Bird 

Feedback on Canada plans to use the |Physical object| hierarchy (specifically < 398124009 |Drug container (physical object)|) for the range of the |Has container type| relationship

6'Drug Therapy' v 'Administration of drug'5Nicola Ingram 

Group feedback sought on 'Drug Therapy' versus 'Administration of Drug' on Discussion Forum

7AOB
All


8Topic Backlog

  • Hydration Subsumption
  • Less Granular Clinical Drug
  • Elemental Substances (Matt, AUS)
  • Substances Co-ordination
    • Step 1: Substances in multiple extensions
    • Step 2: Substances in one extension
    • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
  • Medication Stopped v Medication Discontinued (Karen, SI)
  • Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)
  • Value range of a |Has container type| attribute (Linda, CA)
  • Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
  • Group Input on Patch Strength Representation
  • Dose Form Intended Site v Route of Administration (BEL)
  • Drug extension MRCM attributes (CA, AUS)